Urinary Osteocalcin as a Marker of Bone Metabolism

Ivaska, Kaisa K.; Käkönen, Sanna-Maria; Gerdhem, Paul; Obrant, Karl; Pettersson, Kim; Väänänen, H. Kalervo

doi:10.1373/clinchem.2004.043901

Cited by 72 publications

(58 citation statements)

References 41 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(14) Midmolecular fragments of OC accumulate in urine, and OC fragments measured in urine reflect bone turnover. (15) In this study we show for the first time the usefulness of U-MidOC as a marker of growth. In healthy adults, the ratio of CTX alpha to CTX beta is relatively stable, with the beta form being the predominant one.…”

Section: Discussionmentioning

confidence: 60%

“…U-MidOC was determined with the previously described twosite immunoassay for the OC midfragment. (15) The detection limit for U-MidOC is 0.17 mg/l, (15) and the intra-assay and interassay CVs at 40 mg/l were 2.3% and 7.0%, respectively (n ¼ 32). The levels of U-a-CTX-I and U-b-CTX-I were determined by enzyme-linked immunosorbent assay (ALPHA CrossLaps ELISA and Urine BETA CrossLaps ELISA, IDS Ltd, Boldon, UK).…”

Section: Urinary Samples and Analysesmentioning

confidence: 99%

“…(14) Osteocalcin is metabolised in urine as measurable midmolecule fragments. (15) In adults, urinary osteocalcin (U-MidOC) concentrations correlate with conventional serum markers of bone metabolism assessing bone turnover. (15) U-MidOC can be used in adults as an index of bone turnover.…”

Section: J Jbmrmentioning

confidence: 99%

“…(15) In adults, urinary osteocalcin (U-MidOC) concentrations correlate with conventional serum markers of bone metabolism assessing bone turnover. (15) U-MidOC can be used in adults as an index of bone turnover. (15) It has not yet been evaluated in infants.…”

Section: J Jbmrmentioning

confidence: 99%

“…(15) U-MidOC can be used in adults as an index of bone turnover. (15) It has not yet been evaluated in infants.…”

Section: J Jbmrmentioning

confidence: 99%

See 4 more Smart Citations

Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants

Kilpeläinen

Ivaska

Kuiri-Hänninen

et al. 2012

Journal of Bone and Mineral Research

Self Cite

View full text Add to dashboard Cite

Preterm (PT) infants are at risk of growth failure despite advanced early care and nutrition. In addition to poor weight gain, slow postnatal linear growth also is associated with adverse neurological outcome. Markers distinguishing infants at risk for impaired catch-up growth are needed. The aim of this longitudinal study was to determine the extent to which postnatal levels of circulating cartilage (serum pro-C-type natriuretic peptide [S-proCNP]) and urinary bone metabolic markers (urinary osteocalcin [MidOC] and two forms of C-terminal cross-linked telopeptide of type I collagen [U-a-CTX-I and U-b-CTX-I]) predict catch-up growth in infancy in 67 PT and 58 full-term (FT) infants. PT infants were significantly shorter than FT infants during the first 6 months of life, but no statistically significant difference was found at the corrected age of 14 months (M14). At the age of 3 months (M3), S-ProCNP and U-MidOC levels, but not U-a-CTX-I and U-b-CTX-I levels, correlated positively with prospective growth velocity from M3 to M14 (r ¼ 0.460, p < 0.001 and r ¼ 0.710, p < 0.001, respectively). In predicting slow linear growth (growth velocity at the lowest quartile), the area under the S-ProCNP ROC curve was 0.662 and that of U-MidOC 0.891. Thus, U-MidOC, and to lesser extent S-ProCNP at M3 are predictors of catch-up growth in infancy. ß

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Urinary Samples and Analysesmentioning

confidence: 99%

Section: J Jbmrmentioning

confidence: 99%

Section: J Jbmrmentioning

confidence: 99%

“…(15) U-MidOC can be used in adults as an index of bone turnover. (15) It has not yet been evaluated in infants.…”

Section: J Jbmrmentioning

confidence: 99%

See 3 more Smart Citations

Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants

Kilpeläinen

Ivaska

Kuiri-Hänninen

et al. 2012

Journal of Bone and Mineral Research

Self Cite

View full text Add to dashboard Cite

show abstract

Clinical Chemistry in Toxicity Testing: Scope and Methods

Gosselin

Ramaiah

Earl

2009

General, Applied and Systems Toxicology

View full text Add to dashboard Cite

Noncellular blood compartment (plasma or serum) and urine biochemical components are important indicators of overall animal health and can be used in conjunction with other parameters to investigate the toxicity of drugs and chemicals. This chapter describes the measurement and interpretation of clinical chemistry tests employed in toxicology studies in commonly used laboratory species. The introductory sections delineate methods for sample collection and data generation, and provide a general approach for data interpretation and reporting, with emphasis on distinguishing pre‐analytical/analytical variations from test material‐related changes. The following sections are organized by organ system, describing core clinical chemistry tests used in routine toxicology studies. These include protein, lipid and carbohydrate metabolisms, liver and kidney functions and electrolyte balance. Nonroutine tests evaluating cardiac and skeletal muscle, bone, blood vessels, the endocrine system, the nervous system are also presented. Because few clinical chemistry parameters are specific indicators of single organ toxicity, each section emphasizes the integrated interpretation of biochemistry changes with other study endpoints such as clinical signs, food consumption and bodyweight, haematology, electrocardiography, blood pressure and histopathology. Patterns of change are presented in the context of identifying organ toxicity.

show abstract

Epithelial‐like transport of mineral distinguishes bone formation from other connective tissues

Blair,

Larrouture,

Tourkova

et al. 2023

J of Cellular Biochemistry

View full text Add to dashboard Cite

We review unique properties of bone formation including current understanding of mechanisms of bone mineral transport. We focus on formation only; mechanism of bone degradation is a separate topic not considered. Bone matrix is compared to other connective tissues composed mainly of the same proteins, but without the specialized mechanism for continuous transport and deposition of mineral. Indeed other connective tissues add mechanisms to prevent mineral formation. We start with the epithelial‐like surfaces that mediate transport of phosphate to be incorporated into hydroxyapatite in bone, or in its ancestral tissue, the tooth. These include several phosphate producing or phosphate transport‐related proteins with special expression in large quantities in bone, particularly in the bone‐surface osteoblasts. In all connective tissues including bone, the proteins that constitute the protein matrix are mainly type I collagen and γ−carboxylate‐containing small proteins in similar molar quantities to collagen. Specialized proteins that regulate connective tissue structure and formation are surprisingly similar in mineralized and non‐mineralized tissues. While serum calcium and phosphate are adequate to precipitate mineral, specialized mechanisms normally prevent mineral formation except in bone, where continuous transport and deposition of mineral occurs.

show abstract

Urinary Osteocalcin as a Marker of Bone Metabolism

Cited by 72 publications

References 41 publications

Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants

Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants

Clinical Chemistry in Toxicity Testing: Scope and Methods

Epithelial‐like transport of mineral distinguishes bone formation from other connective tissues

Contact Info

Product

Resources

About